开云app官网登录入口网页版-官方正版

#适应证#

55篇内容 | 2068人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2216010, encodeId=0a14221601093, content=<a href='/topic/show?id=a5452344016' target=_blank style='color:#2F92EE;'>#乙肝病毒#</a> <a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a> <a href='/topic/show?id=72af11691026' target=_blank style='color:#2F92EE;'>#全面治疗#</a>, objectTitle=向治愈乙肝进发！95%中国患者需考虑抗病毒治疗，4类人群应尽快治疗, objectType=article, longId=835479, objectId=81d48354e9e2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719545882221_8538692.jpg, objectUrl=/article/show_article.do?id=81d48354e9e2, replyNumber=0, likeNumber=43, createdTime=2024-07-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=81d48354e9e2, moduleTitle=向治愈乙肝进发！95%中国患者需考虑抗病毒治疗，4类人群应尽快治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=81d48354e9e2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2215374, encodeId=200f22153e40e, content=<a href='/topic/show?id=2c8349102b0' target=_blank style='color:#2F92EE;'>#幽门螺杆菌#</a> <a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=Helicobacter：幽门螺杆菌根除治疗的适应证及其对处方和疗效的影响, objectType=article, longId=834871, objectId=86ef8348e181, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240717/1721183712728_92910.jpg, objectUrl=/article/show_article.do?id=86ef8348e181, replyNumber=0, likeNumber=69, createdTime=2024-07-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=86ef8348e181, moduleTitle=Helicobacter：幽门螺杆菌根除治疗的适应证及其对处方和疗效的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=86ef8348e181)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1893620, encodeId=7944189362031, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=束永前教授：信迪利单抗获批食管鳞癌一线适应证，中国引领的国际性研究ORIENT-15带来高效新选择, objectType=article, longId=730507, objectId=a365e30507cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a365e30507cb, replyNumber=0, likeNumber=0, createdTime=2022-11-10, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a365e30507cb, moduleTitle=束永前教授：信迪利单抗获批食管鳞癌一线适应证，中国引领的国际性研究ORIENT-15带来高效新选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a365e30507cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893619, encodeId=99ba189361913, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=沈琳教授：信迪利单抗成功问鼎一线食管鳞癌适应证，高质量ORIENT-15彰显非凡“食”力, objectType=article, longId=730159, objectId=7915e301596b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7915e301596b, replyNumber=0, likeNumber=72, createdTime=2023-02-20, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7915e301596b, moduleTitle=沈琳教授：信迪利单抗成功问鼎一线食管鳞癌适应证，高质量ORIENT-15彰显非凡“食”力, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7915e301596b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893621, encodeId=a4b418936218c, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=张艳桥教授：信迪利单抗收获第6项新适应证，晚期胃癌一线治疗利刃出鞘, objectType=article, longId=731240, objectId=5c5ee312408b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c5ee312408b, replyNumber=0, likeNumber=87, createdTime=2022-09-08, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c5ee312408b, moduleTitle=张艳桥教授：信迪利单抗收获第6项新适应证，晚期胃癌一线治疗利刃出鞘, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5c5ee312408b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893618, encodeId=29f5189361852, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=指南共识 | 2021年欧洲指南：成人和儿童患者氢和甲烷呼气试验的适应证、表现和临床影响, objectType=article, longId=728005, objectId=47e6e28005e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47e6e28005e3, replyNumber=0, likeNumber=93, createdTime=2023-03-28, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47e6e28005e3, moduleTitle=指南共识 | 2021年欧洲指南：成人和儿童患者氢和甲烷呼气试验的适应证、表现和临床影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=47e6e28005e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893613, encodeId=4235189361302, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=房颤导管消融的适应证, objectType=article, longId=214322, objectId=22d1214322f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22d1214322f0, replyNumber=0, likeNumber=0, createdTime=2022-03-21, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22d1214322f0, moduleTitle=房颤导管消融的适应证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=22d1214322f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893617, encodeId=136c189361e03, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？, objectType=article, longId=724077, objectId=f67de2407786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f67de2407786, replyNumber=0, likeNumber=106, createdTime=2023-01-02, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f67de2407786, moduleTitle=PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f67de2407786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893616, encodeId=61d01893616f7, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=祝贺贝伐珠单抗在中国新增两项适应证, objectType=article, longId=220986, objectId=b1b1220986e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b1220986e9, replyNumber=0, likeNumber=76, createdTime=2022-09-13, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b1220986e9, moduleTitle=祝贺贝伐珠单抗在中国新增两项适应证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b1b1220986e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893615, encodeId=b733189361548, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=新型磷结合剂「碳酸司维拉姆」在华获批又一适应证，为非透析慢性肾脏病高磷血症人群提供治疗新选择, objectType=article, longId=219666, objectId=256921966684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=256921966684, replyNumber=0, likeNumber=82, createdTime=2022-05-21, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=256921966684, moduleTitle=新型磷结合剂「碳酸司维拉姆」在华获批又一适应证，为非透析慢性肾脏病高磷血症人群提供治疗新选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=256921966684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893612, encodeId=3609189361219, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=袁祖贻教授：瑞舒伐他汀新适应证中国获批——关注斑块早期识别诊断，遵循指南延缓斑块进展, objectType=article, longId=213785, objectId=95b8213e8560, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95b8213e8560, replyNumber=0, likeNumber=0, createdTime=2022-03-14, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95b8213e8560, moduleTitle=袁祖贻教授：瑞舒伐他汀新适应证中国获批——关注斑块早期识别诊断，遵循指南延缓斑块进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=95b8213e8560)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893614, encodeId=e11f18936142b, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=额颞开颅翼点入路的适应证有哪些？, objectType=article, longId=214415, objectId=8e27214415b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e27214415b3, replyNumber=0, likeNumber=70, createdTime=2022-07-04, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e27214415b3, moduleTitle=额颞开颅翼点入路的适应证有哪些？, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8e27214415b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893611, encodeId=383d189361145, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=帕博利珠单抗获批新增剂量方案适用在华获批的6个适应证, objectType=article, longId=208569, objectId=942c20856917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=942c20856917, replyNumber=0, likeNumber=78, createdTime=2021-05-31, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=942c20856917, moduleTitle=帕博利珠单抗获批新增剂量方案适用在华获批的6个适应证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=942c20856917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893610, encodeId=578618936104d, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, objectType=article, longId=205805, objectId=fa1f20580549, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa1f20580549, replyNumber=0, likeNumber=76, createdTime=2021-12-07, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa1f20580549, moduleTitle=FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fa1f20580549)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893608, encodeId=b20e1893608f3, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=魏强教授：替雷利珠单抗获批晚期尿路上皮癌治疗适应证, objectType=article, longId=193190, objectId=7fc8193190c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fc8193190c2, replyNumber=0, likeNumber=78, createdTime=2020-08-21, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fc8193190c2, moduleTitle=魏强教授：替雷利珠单抗获批晚期尿路上皮癌治疗适应证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7fc8193190c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893609, encodeId=d652189360910, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=Circulation：他汀治疗适应证还应进一步扩大！, objectType=article, longId=198308, objectId=c9f51983081b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f51983081b, replyNumber=0, likeNumber=95, createdTime=2020-09-19, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f51983081b, moduleTitle=Circulation：他汀治疗适应证还应进一步扩大！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c9f51983081b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893606, encodeId=5024189360644, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大, objectType=article, longId=183912, objectId=fc8b1839120b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc8b1839120b, replyNumber=0, likeNumber=0, createdTime=2019-12-17, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc8b1839120b, moduleTitle=中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fc8b1839120b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893607, encodeId=c521189360e3e, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=从全新共识把握生酮饮食疗法的适应证和禁忌证, objectType=article, longId=185121, objectId=0604185121e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0604185121e9, replyNumber=0, likeNumber=62, createdTime=2020-08-14, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0604185121e9, moduleTitle=从全新共识把握生酮饮食疗法的适应证和禁忌证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0604185121e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893605, encodeId=c544189360597, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=2019 跨学科共识：经股动脉导管主动脉瓣植入术(TF‑TAVI)的适应证, objectType=article, longId=178043, objectId=e2101e804300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2101e804300, replyNumber=0, likeNumber=62, createdTime=2019-12-23, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2101e804300, moduleTitle=2019 跨学科共识：经股动脉导管主动脉瓣植入术(TF‑TAVI)的适应证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e2101e804300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1893601, encodeId=a06b1893601f7, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, objectTitle=2019 临床实践指南：Mohs显微外科手术的适应证, objectType=article, longId=163210, objectId=7761163210e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7761163210e2, replyNumber=0, likeNumber=69, createdTime=2020-02-09, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7761163210e2, moduleTitle=2019 临床实践指南：Mohs显微外科手术的适应证, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7761163210e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

适应证

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乙肝病毒# #适应证# #全面治疗#

向治愈乙肝进发！95%中国患者需考虑抗病毒治疗，4类人群应尽快治疗

2024-07-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#幽门螺杆菌# #适应证#

Helicobacter：幽门螺杆菌根除治疗的适应证及其对处方和疗效的影响

2024-07-17发表于上海

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

束永前教授：信迪利单抗获批食管鳞癌一线适应证，中国引领的国际性研究ORIENT-15带来高效新选择

2022-11-10

docwu2019 (审核中...)

前往app查看评论内容

#适应证#

沈琳教授：信迪利单抗成功问鼎一线食管鳞癌适应证，高质量ORIENT-15彰显非凡“食”力

2023-02-20

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

张艳桥教授：信迪利单抗收获第6项新适应证，晚期胃癌一线治疗利刃出鞘

2022-09-08

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

指南共识 | 2021年欧洲指南：成人和儿童患者氢和甲烷呼气试验的适应证、表现和临床影响

2023-03-28

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

房颤导管消融的适应证

2022-03-21

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

PD-1/PD-L1药物治疗起效后，何时能停？获批适应证有哪些？

2023-01-02

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

祝贺贝伐珠单抗在中国新增两项适应证

2022-09-13

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

新型磷结合剂「碳酸司维拉姆」在华获批又一适应证，为非透析慢性肾脏病高磷血症人群提供治疗新选择

2022-05-21

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

袁祖贻教授：瑞舒伐他汀新适应证中国获批——关注斑块早期识别诊断，遵循指南延缓斑块进展

2022-03-14

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

额颞开颅翼点入路的适应证有哪些？

2022-07-04

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

帕博利珠单抗获批新增剂量方案适用在华获批的6个适应证

2021-05-31

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

FDA批准辉瑞ALK抑制剂克唑替尼新适应证：ALK阳性间变性大细胞淋巴瘤

2021-12-07

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

魏强教授：替雷利珠单抗获批晚期尿路上皮癌治疗适应证

2020-08-21

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

Circulation：他汀治疗适应证还应进一步扩大！

2020-09-19

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大

2019-12-17

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

从全新共识把握生酮饮食疗法的适应证和禁忌证

2020-08-14

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

2019 跨学科共识：经股动脉导管主动脉瓣植入术(TF‑TAVI)的适应证

2019-12-23

muzishouyi (审核中...)

前往app查看评论内容

#适应证#

2019 临床实践指南：Mohs显微外科手术的适应证

2020-02-09

科室
- - 订阅+
  - 更多科室
工具
服务